HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clinical and immunological characteristics of patients with 2009 pandemic influenza A (H1N1) virus infection after vaccination.

AbstractBACKGROUND:
We followed a cohort of 773 individuals who received a monovalent vaccine against 2009 pandemic influenza A (H1N1). Approximately 6 weeks after vaccination, 12 persons developed the disease.
METHODS:
Three groups of subjects were studied (12 patients who had or had not received previous monovalent vaccine and 1 group of 49 control subjects who had previously been immunized with the same vaccine). For all patients, clinical features were characterized and the causative viruses sequenced for possible mutations. Nasopharyngeal swabs, serum specimens, and peripheral blood monocyte cells (PBMCs) were collected at different time points up to 11 weeks after symptom onset to measure the virus load and humoral and cellular immune responses. Serum samples and PBMCs were also collected from 49 and 16 vaccinated control subjects, respectively.
RESULTS:
Both patient groups had similar clinical manifestations. No substantial viral mutations were detected. Compared with unvaccinated patients, viral loads in vaccinated patients were initially higher, but the levels decreased faster to undetectable levels. However, the virus became detectable again for 6 of them. Two weeks after infection, vaccinated and unvaccinated patients had similar neutralizing antibody levels as the vaccinated control subjects. Thereafter, the neutralizing antibody levels decreased markedly in vaccinated patients. During the acute phase, memory T cell counts and tumor necrosis factor-α levels were significantly higher in vaccinated than in unvaccinated patients.
CONCLUSIONS:
Although the clinical consequences of infection are comparable between vaccinated and unvaccinated patients, humoral and cellular immune responses in vaccinated patients are boosted for some weeks, indicating an additional benefit of vaccination against 2009 pandemic influenza A (H1N1) virus.
AuthorsWei Liu, Sake J de Vlas, Fang Tang, Mai-Juan Ma, Mao-Ti Wei, Li-Juan Liu, Zeng-De Li, Lei Zhang, Zhong-Tao Xin, Yi-Gang Tong, Tao Jiang, Xiao-Ai Zhang, Cui He, Chris Li, Xiao-Ning Xu, Hong Yang, Jan Hendrik Richardus, Wu-Chun Cao
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 51 Issue 9 Pg. 1028-32 (Nov 01 2010) ISSN: 1537-6591 [Electronic] United States
PMID20887209 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Viral
  • Influenza Vaccines
Topics
  • Adolescent
  • Adult
  • Antibodies, Viral (blood)
  • Blood (immunology, virology)
  • Cohort Studies
  • Female
  • Humans
  • Influenza A Virus, H1N1 Subtype (isolation & purification)
  • Influenza Vaccines (administration & dosage)
  • Influenza, Human (immunology, pathology, virology)
  • Leukocytes, Mononuclear (immunology)
  • Male
  • Nasopharynx (virology)
  • Viral Load
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: